Does the media favor RAPP or STRO?

In the previous week, Rapport Therapeutics had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 6 mentions for Rapport Therapeutics and 4 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.97 beat Rapport Therapeutics' score of 0.52 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NBTX or STRO?

Nanobiotix has higher earnings, but lower revenue than Sutro Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 46.77 -$27.11M N/A N/A Sutro Biopharma $102.48M 4.66 -$191.09M -$11.04 N/A

Is NBTX or STRO more profitable?

Nanobiotix has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Sutro Biopharma -154.21% N/A -69.20%

Does the media prefer NBTX or STRO?

In the previous week, Sutro Biopharma had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Sutro Biopharma and 3 mentions for Nanobiotix. Sutro Biopharma's average media sentiment score of 0.97 beat Nanobiotix's score of 0.96 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or STRO?

In the previous week, AbCellera Biologics had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 6 mentions for AbCellera Biologics and 4 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.97 beat AbCellera Biologics' score of 0.56 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STRO or AGIO?

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 4 mentions for Sutro Biopharma. Agios Pharmaceuticals' average media sentiment score of 1.10 beat Sutro Biopharma's score of 0.97 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, STRO or NUVB?

Sutro Biopharma has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sutro Biopharma $102.48M 4.66 -$191.09M -$11.04 N/A Nuvation Bio $62.90M 27.15 -$204.63M -$0.43 N/A

Does the media prefer STRO or NUVB?

In the previous week, Nuvation Bio had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Sutro Biopharma. Nuvation Bio's average media sentiment score of 1.23 beat Sutro Biopharma's score of 0.97 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sutro Biopharma (STRO) Competitors

$28.80 +2.32 (+8.76%)

Closing price 04:00 PM Eastern

Extended Trading

$28.87 +0.07 (+0.24%)

As of 05:52 PM Eastern

Compare

STRO vs. RAPP, NBTX, ABCL, AGIO, and NUVB

Should you buy Sutro Biopharma stock or one of its competitors? MarketBeat compares Sutro Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sutro Biopharma include Rapport Therapeutics (RAPP), Nanobiotix (NBTX), AbCellera Biologics (ABCL), Agios Pharmaceuticals (AGIO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.

How does Sutro Biopharma compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Rapport Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Rapport Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Sutro Biopharma	$102.48M	4.66	-$191.09M	-$11.04	N/A

97.0% of Sutro Biopharma shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rapport Therapeutics had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 6 mentions for Rapport Therapeutics and 4 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.97 beat Rapport Therapeutics' score of 0.52 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Sutro Biopharma	-154.21%	N/A	-69.20%

Rapport Therapeutics presently has a consensus target price of $58.83, indicating a potential upside of 53.21%. Sutro Biopharma has a consensus target price of $49.20, indicating a potential upside of 70.83%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

Sutro Biopharma beats Rapport Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Sutro Biopharma had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Sutro Biopharma and 3 mentions for Nanobiotix. Sutro Biopharma's average media sentiment score of 0.97 beat Nanobiotix's score of 0.96 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

Nanobiotix presently has a consensus target price of $37.33, indicating a potential upside of 5.05%. Sutro Biopharma has a consensus target price of $49.20, indicating a potential upside of 70.83%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Nanobiotix has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Sutro Biopharma	-154.21%	N/A	-69.20%

Nanobiotix has higher earnings, but lower revenue than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	46.77	-$27.11M	N/A	N/A
Sutro Biopharma	$102.48M	4.66	-$191.09M	-$11.04	N/A

Summary

Sutro Biopharma beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

How does Sutro Biopharma compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

AbCellera Biologics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

In the previous week, AbCellera Biologics had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 6 mentions for AbCellera Biologics and 4 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.97 beat AbCellera Biologics' score of 0.56 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics presently has a consensus price target of $7.80, indicating a potential upside of 48.85%. Sutro Biopharma has a consensus price target of $49.20, indicating a potential upside of 70.83%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AbCellera Biologics has higher earnings, but lower revenue than Sutro Biopharma. AbCellera Biologics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	21.30	-$146.41M	-$0.48	N/A
Sutro Biopharma	$102.48M	4.66	-$191.09M	-$11.04	N/A

Sutro Biopharma has a net margin of -154.21% compared to AbCellera Biologics' net margin of -181.75%. Sutro Biopharma's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Sutro Biopharma	-154.21%	N/A	-69.20%

Summary

Sutro Biopharma beats AbCellera Biologics on 11 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to Agios Pharmaceuticals?

Sutro Biopharma (NASDAQ:STRO) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 4 mentions for Sutro Biopharma. Agios Pharmaceuticals' average media sentiment score of 1.10 beat Sutro Biopharma's score of 0.97 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sutro Biopharma has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.66	-$191.09M	-$11.04	N/A
Agios Pharmaceuticals	$66.05M	26.53	-$412.78M	-$7.25	N/A

Sutro Biopharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Sutro Biopharma presently has a consensus price target of $49.20, suggesting a potential upside of 70.83%. Agios Pharmaceuticals has a consensus price target of $40.89, suggesting a potential upside of 38.79%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sutro Biopharma is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Sutro Biopharma has a net margin of -154.21% compared to Agios Pharmaceuticals' net margin of -639.84%. Sutro Biopharma's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

97.0% of Sutro Biopharma shares are held by institutional investors. 3.6% of Sutro Biopharma shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sutro Biopharma beats Agios Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to Nuvation Bio?

Sutro Biopharma (NASDAQ:STRO) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Sutro Biopharma presently has a consensus target price of $49.20, suggesting a potential upside of 70.83%. Nuvation Bio has a consensus target price of $12.50, suggesting a potential upside of 154.84%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Sutro Biopharma has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

In the previous week, Nuvation Bio had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Sutro Biopharma. Nuvation Bio's average media sentiment score of 1.23 beat Sutro Biopharma's score of 0.97 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvation Bio has a net margin of -102.06% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Sutro Biopharma has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.66	-$191.09M	-$11.04	N/A
Nuvation Bio	$62.90M	27.15	-$204.63M	-$0.43	N/A

Summary

Sutro Biopharma beats Nuvation Bio on 9 of the 17 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$477.22M	$3.37B	$6.49B	$11.98B
Dividend Yield	N/A	2.32%	2.67%	5.57%
P/E Ratio	-2.61	19.65	23.85	24.45
Price / Sales	4.66	312.51	572.24	136.74
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	-1.87	8.32	10.66	6.80
Net Income	-$191.09M	$23.89M	$3.56B	$337.76M
7 Day Performance	10.39%	0.94%	0.05%	2.08%
1 Month Performance	-29.60%	-1.16%	0.37%	3.16%
1 Year Performance	254.99%	41.51%	22.73%	27.78%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	4.2344 of 5 stars	$28.80 +8.8%	$49.20 +70.8%	+220.3%	$477.22M	$102.48M	N/A	240	Analyst Forecast Short Interest Decrease
RAPP Rapport Therapeutics	2.7608 of 5 stars	$36.68 +1.6%	$58.83 +60.4%	+191.0%	$1.73B	N/A	N/A	N/A
NBTX Nanobiotix	3.6128 of 5 stars	$35.88 +1.2%	$37.33 +4.1%	+598.9%	$1.72B	$36.87M	N/A	100	Short Interest Decrease Gap Down
ABCL AbCellera Biologics	2.3605 of 5 stars	$5.42 -3.6%	$7.80 +43.9%	+63.2%	$1.72B	$75.13M	N/A	500	Gap Up
AGIO Agios Pharmaceuticals	3.3421 of 5 stars	$27.44 -3.0%	$41.44 +51.0%	-16.5%	$1.68B	$54.03M	N/A	390	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. RAPP, NBTX, ABCL, AGIO, and NUVB

How does Sutro Biopharma compare to Rapport Therapeutics?

Summary

How does Sutro Biopharma compare to Nanobiotix?

Summary

How does Sutro Biopharma compare to AbCellera Biologics?

Summary

How does Sutro Biopharma compare to Agios Pharmaceuticals?

Summary

How does Sutro Biopharma compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. RAPP, NBTX, ABCL, AGIO, and NUVB

How does Sutro Biopharma compare to Rapport Therapeutics?

Which has more volatility & risk, RAPP or STRO?

Which has preferable valuation and earnings, RAPP or STRO?

Do institutionals and insiders believe in RAPP or STRO?

Does the media favor RAPP or STRO?

Is RAPP or STRO more profitable?

Do analysts rate RAPP or STRO?

Summary

How does Sutro Biopharma compare to Nanobiotix?

Do institutionals & insiders believe in NBTX or STRO?

Does the media prefer NBTX or STRO?

Which has more volatility & risk, NBTX or STRO?

Do analysts prefer NBTX or STRO?

Is NBTX or STRO more profitable?

Which has better valuation & earnings, NBTX or STRO?

Summary

How does Sutro Biopharma compare to AbCellera Biologics?

Which has more risk and volatility, ABCL or STRO?

Does the media refer more to ABCL or STRO?

Do analysts rate ABCL or STRO?

Do institutionals and insiders believe in ABCL or STRO?

Which has preferable valuation and earnings, ABCL or STRO?

Is ABCL or STRO more profitable?

Summary

How does Sutro Biopharma compare to Agios Pharmaceuticals?

Does the media favor STRO or AGIO?

Which has stronger earnings and valuation, STRO or AGIO?

Which has more volatility & risk, STRO or AGIO?

Do analysts rate STRO or AGIO?

Is STRO or AGIO more profitable?

Do institutionals & insiders have more ownership in STRO or AGIO?

Summary

How does Sutro Biopharma compare to Nuvation Bio?

Do analysts recommend STRO or NUVB?

Which has more volatility & risk, STRO or NUVB?

Does the media prefer STRO or NUVB?

Do institutionals & insiders hold more shares of STRO or NUVB?

Is STRO or NUVB more profitable?

Which has better valuation and earnings, STRO or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools